A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus.

2.50
Hdl Handle:
http://hdl.handle.net/10033/87413
Title:
A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus.
Authors:
Schulze, Kai ( 0000-0003-2286-3416 ) ; Staib, Caroline; Schätzl, Hermann M; Ebensen, Thomas ( 0000-0001-8906-063X ) ; Erfle, Volker; Guzman, Carlos A
Abstract:
Severe acute respiratory syndrome (SARS) is a serious infectious disease caused by the SARS coronavirus. We assessed the potential of prime-boost vaccination protocols based on the nucleocapsid (NC) protein co-administered with a derivative of the mucosal adjuvant MALP-2 or expressed by modified Vaccinia virus Ankara (MVA-NC) to stimulate humoral and cellular immune responses at systemic and mucosal levels. The obtained results demonstrated that strong immune responses can be elicited both at systemic and mucosal levels following a heterologous prime-boost vaccination protocol consisting in priming with NC protein add-mixed with MALP-2 by intranasal route and boosting with MVA-NC by intramuscular route.
Affiliation:
Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7, D-38124 Braunschweig, Germany.
Citation:
A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus. 2008, 26 (51):6678-84 Vaccine
Journal:
Vaccine
Issue Date:
2-Dec-2008
URI:
http://hdl.handle.net/10033/87413
DOI:
10.1016/j.vaccine.2008.09.006
PubMed ID:
18805454
Type:
Article
Language:
en
ISSN:
0264-410X
Appears in Collections:
publications of the research group vaccinology and applied microbiology (VAC)

Full metadata record

DC FieldValue Language
dc.contributor.authorSchulze, Kaien
dc.contributor.authorStaib, Carolineen
dc.contributor.authorSchätzl, Hermann Men
dc.contributor.authorEbensen, Thomasen
dc.contributor.authorErfle, Volkeren
dc.contributor.authorGuzman, Carlos Aen
dc.date.accessioned2009-12-04T12:59:14Zen
dc.date.available2009-12-04T12:59:14Zen
dc.date.issued2008-12-02en
dc.identifier.citationA prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus. 2008, 26 (51):6678-84 Vaccineen
dc.identifier.issn0264-410Xen
dc.identifier.pmid18805454en
dc.identifier.doi10.1016/j.vaccine.2008.09.006en
dc.identifier.urihttp://hdl.handle.net/10033/87413en
dc.description.abstractSevere acute respiratory syndrome (SARS) is a serious infectious disease caused by the SARS coronavirus. We assessed the potential of prime-boost vaccination protocols based on the nucleocapsid (NC) protein co-administered with a derivative of the mucosal adjuvant MALP-2 or expressed by modified Vaccinia virus Ankara (MVA-NC) to stimulate humoral and cellular immune responses at systemic and mucosal levels. The obtained results demonstrated that strong immune responses can be elicited both at systemic and mucosal levels following a heterologous prime-boost vaccination protocol consisting in priming with NC protein add-mixed with MALP-2 by intranasal route and boosting with MVA-NC by intramuscular route.en
dc.language.isoenen
dc.subject.meshAdjuvants, Immunologicen
dc.subject.meshAdministration, Intranasalen
dc.subject.meshAnimalsen
dc.subject.meshAntibodies, Viralen
dc.subject.meshImmunity, Cellularen
dc.subject.meshImmunization, Secondaryen
dc.subject.meshImmunoglobulin Aen
dc.subject.meshInjections, Intramuscularen
dc.subject.meshLipopeptidesen
dc.subject.meshMiceen
dc.subject.meshMice, Inbred BALB Cen
dc.subject.meshNucleocapsid Proteinsen
dc.subject.meshSARS Virusen
dc.subject.meshSevere Acute Respiratory Syndromeen
dc.subject.meshVaccinia virusen
dc.subject.meshViral Vaccinesen
dc.titleA prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus.en
dc.typeArticleen
dc.contributor.departmentDepartment of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7, D-38124 Braunschweig, Germany.en
dc.identifier.journalVaccineen

Related articles on PubMed

This item is licensed under a Creative Commons License
Creative Commons
All Items in HZI are protected by copyright, with all rights reserved, unless otherwise indicated.